Endotheliitis is an important histologic feature of acute cellular rejection (ACR) in the liver allograft. This change is not specific, however, and has been suggested to be associated with various liver diseases. End-stage liver disease owing to chronic hepatitis C is the leading indication for transplantation in North America, and its recurrence in allograft recipients is common. Because the presence of endotheliitis remains a diagnostic and therapeutic dilemma in transplant pathology, we investigated the prevalence and severity of endotheliitis in chronic liver diseases including hepatitis C. Endotheliitis was evaluated in 128 nontransplant liver biopsies of chronic liver diseases before therapy, including hepatitis C (HCV, n = 62), hepatitis B (HBV, n = 17), and nonalcoholic steatohepatitis (NASH, n = 49). Eighty posttransplant biopsies with ACR were also reviewed. Subendothelial and supraendothelial endotheliitis were separately scored in the portal and central regions using a semiquantitative scoring system from 0 to 4. Pathologists were blinded to the clinical histories, and each biopsy was independently scored by 2 pathologists. Histologic activity index was also scored subsequently for cases of chronic HCV and HBV, using the modified Knodell (Ishak) score. Mean endotheliitis scores 41 were seen in 60%, 35%, and 6% of HCV, HBV, and NASH patients, respectively. The scores for portal subendotheliitis and supraendotheliitis were significantly higher in the viral hepatitis group than in the NASH group (P<0.01). There was no significant difference in the scores of endotheliitis comparing HCV to HBV. ACR group showed significantly higher scores in both portal and central subendotheliitis than any other group (P<0.00005). In the HBV and HCV groups with mean scores of portal subendotheliitis 41 (n = 44), mean Ishak scores for portal inflammation and periportal injury were 2.43 and 2.34, respectively; whereas in those with less severe portal subendotheliitis (r1, n = 35), Ishak scores were 1.66 and 1.37, respectively (P = 0.00001 for portal inflammation and P = 0.00001 for periportal injury, respectively). Our results suggest that minimal to mild subendotheliitis is common in portal veins in chronic hepatitis C and B, but is significantly less intense than that seen in ACR. The degree of endotheliitis correlates with inflammatory activity. These observations may help minimize the risk of overdiagnosing ACR when the patient has recurrent viral hepatitis, and may help clinicians avoid exposing patients to unnecessary immunosuppressive regimens when patients do not have cellular rejection.
T he diagnosis of acute cellular rejection (ACR) in the liver allograft relies on the presence of portal inflammatory infiltrates, lymphocytic cholangitis, and endotheliitis. 5 However, these changes are not specific for ACR. Of these histologic features, endotheliitis in particular may also be associated with various liver diseases, 13 including chronic hepatitis B, hepatitis C, and autoimmune hepatitis. End-stage liver disease (ie, cirrhosis) and/or hepatocellular carcinoma owing to chronic hepatitis C are the leading indications for liver transplantation in North America and Europe and recurrence of hepatitis C in the allograft is almost universal in patients transplanted for this disease. Pathologists, working together with hepatologists and transplant surgeons, often face a significant clinical challenge of deciding whether or not the presence of inflammatory cells, especially lymphocytes underneath venular endothelium, warrants a diagnosis of ACR. The therapeutic implications of this interpretative problem are significant, because increase in and/or addition of immunosuppressive medications may be precipitated by a diagnosis of rejection. Posttransplant patients are more susceptible to various opportunistic infections and/or exacerbation of recurrent hepatitis C when exposed to such regimen alterations. These complications are unacceptable (especially if they are avoidable) in patients who are not rejecting their allograft. For these reasons, the presence of endotheliitis remains a diagnostic and therapeutic dilemma in liver transplant pathology. In an attempt to at least partially resolve the morphologic constraints on the use of documenting endotheliitis in the separation of recurrent viral hepatitis from ACR, we investigated the prevalence and severity of endotheliitis in chronic liver diseases, with particular emphasis on hepatitis C.
MATERIALS AND METHODS
The study protocol was reviewed and approved by the Human Subject Division at the University of Washington. We completed a retrospective review of 128 nontransplant liver biopsies of chronic liver diseases; cases sampled in this review include hepatitis C (HCV group, n = 62), hepatitis B (HBV group, n = 17), and nonalcoholic steatohepatitis (NASH group, n = 49). In parallel, a group of posttransplant liver biopsies with a diagnosis of uncomplicated ACR were also reviewed. These biopsies were performed for abnormal liver function tests or as routine posttransplant protocol procedures. The diagnoses of ACR were reviewed both histologically and clinically, including clinical abnormality of liver function tests with improvement after booster immunotherapy, and subtherapeutic level of immunosuppressive agents. Cases with evidence of biliary obstruction, ischemia, chronic rejection, recurrent diseases, and infection were excluded from the ACR group. After further excluding the biopsies in which a current histologic review did not have unequivocal evidence of ACR, 80 biopsies of definitive ACR were included (ACR group, n = 80). Cases drawn from the Surgical Pathology files at the University of Washington Medical Center (Division of Anatomic Pathology) were accessioned between 1990 and 2004. Liver biopsy in HCV and HBV groups had been performed for pretreatment evaluation and none of the affected individuals received any antiviral therapy before biopsy. A 16-gauge Klatskin needle and the Menghini technique were used to obtain all liver biopsy specimens. Clinical data confirming HCV and HBV infection were reviewed, including HCV serology, HCV RNA polymerase chain reaction, HBV serology, and HBV DNA polymerase chain reaction. There was no serologic and virologic evidence of HBV/HCV coinfection in either group. Liver biopsy using the same technique was performed in the NASH group for the establishment of diagnosis of steatohepatitis and for exclusion of other concomitant liver diseases. No patient in the NASH group had evidence of hepatitis B or C or any other liver disease. Clinical data, including sex, age, serum liver studies [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and international normalized ratio (INR)], and HCV genotype were obtained. At the outset, 3 pathologists (P.E.S., M.P.U., and M.M.Y.) agreed on a semiquantitative scoring system for endotheliitis from 0 to 4 (Table 1 ). Subendothelial and supraendothelial endotheliitis were separately scored in both the portal and central regions (Figs. 1A-C). To validate this scoring method, 2 pathologists (M.P.U. and M.M.Y.) independently scored endotheliitis for each liver biopsy. k values for interobserver variation were calculated. Pathologists were blinded to the patients' clinical histories at the time biopsies were reviewed. Histologic activity index (HAI) was also scored subsequently for cases of chronic hepatitis C and B, using the modified Knodell (Ishak) score. 11 The scoring system for endotheliitis designed for the current study is not without some logistic concern. Although there is a clear distinction in severity between endotheliitis scored as 1 and that scored as 4, the relationship between scores 2 or 3 is less clear. We defined these intermediate scores to allow a more detailed database to be created, on the assumption that those patterns defined as score 3 represented a more extensive pattern of vascular injury than score 2 lesions. However, it remains plausible that with this system, a score of 2 could represent a more severe endotheliitis than a score of 3 in selected cases. Therefore, we also analyzed all histologic observations using a 3-tier scoring system in which both intermediate scores in the 4-tier paradigm were scored together as 2, and lesions originally defined as score 4 were reassigned a value of 3.
Statistical analyses were performed using Stata 8.0 software (StataCorp LP, College Station TX). Data are presented as means ± SD, numbers and percentages, except where noted. In the analysis of continuous data, the Students t test was used. In the analysis of nominal data, the w 2 test or analysis of variance was used to examine differences between groups when there were 2 or more possible values, and Fisher exact test used if the number of subjects in any group was under 10. 
RESULTS

Demographics, Liver Function Tests, and HCV Genotypes
The sex, age, and liver function tests for each group are shown in Table 2 . There were 45 men in the HCV group (72%), 8 men in the HBV group (47%), and 26 men in the NASH group (53%), suggesting a male predilection in the HCV group, but not in the HBV or NASH group. The mean ages for these 3 groups were 44, 34, and 44, respectively ( Table 2 ). Laboratory indices at the time of biopsy, including AST, ALT, total bilirubin, alkaline phosphatase, and INR are shown in Table 2 . There was no significant difference in liver function tests between the HCV and HBV groups and between the HBV and NASH groups. The mean AST and ALT were higher in the HCV group than in the NASH group (P = 0.03 and 0.02, respectively), but the remaining liver studies were similar. When the HCV and HBV groups were combined, ALT was the only parameter that was significantly higher than that observed in the NASH group (P = 0.02).
Forty-three HCV patients (69%) had information regarding genotype available, among which 36 (84%) were genotype 1 (23-1a and 13-1b), 5 (8%) genotype 2, and 2 (4%) genotype 3.
Validation of Scoring Method for Endotheliitis
As noted earlier, a semiquantitative score for endotheliitis was devised and applied in all cases (Table 1) . To evaluate variation in results between the 2 pathologists independently applying this scoring system (M.P.U., M.M.Y.), k values were calculated (Table 3) . Essentially there was substantial concordance between the 2 pathologists in scoring supraendotheliitis and subendotheliitis, with all k values greater than 60%, effectively validating the scoring methodology.
Portal Endotheliitis Score is Higher in the Viral Hepatitis Group Than in the NASH Group
In the portal regions, mean subendotheliitis scores 41 were obtained in 60%, 35%, and 6% of patients in the HCV, HBV, and NASH groups, respectively. As shown in Table 3 , the scores for portal subendotheliitis were significantly higher in the viral hepatitis group (HBV and HCV combined) than in the NASH group (1.67 ± 1.09 vs. 0.39 ± 0.79, pathologist 1 and 1.51 ± 1.02 vs. 0.31 ± 0.68, pathologist 2, P = 0.00001 for both pathologists). When HBV and HCV groups were FIGURE 1. A, Liver biopsy from a patient with chronic hepatitis C. Inflammatory cells composed predominantly of lymphocytes infiltrating underneath the endothelial surface in less than 50% of the circumference of the portal vein are seen (hematoxylin and eosin, Â 400). B, Liver biopsy from a patient with chronic hepatitis C. In this portal tract, inflammatory cells predominantly composed of lymphocytes are seen infiltrating underneath the endothelial surface of almost the whole circumference of the portal vein (hematoxylin and eosin, Â 400). C, In this liver biopsy from a patient with chronic hepatitis C, 4 lymphocytes are seen attached to the endothelial surface of a portal vein (arrows) via their cytoplasmic processes (hematoxylin and eosin, Â 400). D, A liver biopsy showing ACR. In the portal tract, prominent eosinophils are present and blastlike lymphocytes are infiltrating, undermining, and lifting the endothelial cells, which seem to be reactive. Lymphocytes also infiltrate the adjacent bile duct (arrow, hematoxylin and eosin, Â 400). compared with the NASH group separately, the scores for portal subendotheliitis were also significantly higher in both HBV and HCV groups than those in the NASH group. Between HBV and HCV groups, there were no significant differences in any category of endotheliitis. When central vein subendotheliitis was assessed, comparing combined HCV and HBV groups with the NASH group, a significant difference was observed in the scores obtained from pathologist 2: viral hepatitis 0.42 ± 0.50 and NASH 0.20 ± 0.54 (P = 0.03). Otherwise, in the central region, although the overall mean scores for endotheliitis in HBV and HCV groups seemed higher than those seen in the NASH group, they did not reach statistical significance. Similarly, there was no significant difference in supraendotheliitis between viral hepatitis and NASH groups. However, portal supraendotheliitis score was significantly higher in the viral hepatitis group than in the NASH group, a finding that was largely due to the presence of increased supraendothelial portal vein damage in the HCV group. Table 4 shows the correlation between the severity of portal subendotheliitis and the HAI for portal inflammation and periportal injury in the viral hepatitis groups. In the HBV and HCV groups with mean scores (2 pathologists) of portal subendotheliitis 41 (n = 44), average HAI for portal inflammation was 2.57 ± 0.70 (pathologist 1) and 2.30 ± 0.67 (pathologist 2), whereas those with less severe portal subendotheliitis (r1, n = 35), average HAI for portal inflammation was 1.76 ± 0.89 (pathologist 1) and 1.56 ± 0.70 (pathologist 2). These findings indicate a strong correlation between the degree of subendotheliitis and the HAI for portal inflammation (P = 0.00001 for both pathologists). Similarly, average HAI for periportal injury was 2.55 ± 0.85 (pathologist 1) and 2.14 ± 1.13 (pathologist 2) when the mean scores (both pathologists) for portal subendotheliitis were greater than 1, whereas average HAI for periportal injury was 1.53 ± 1.08 (pathologist 1) and 1.21 ± 1.09 (pathologist 2) when the mean scores for portal subendotheliitis was r1. A significant correlation between the degree of periportal injury and severity of portal subendotheliitis was also noted (P = 0.00001 for pathologist 1 and P = 0.0005 for pathologist 2, respectively).
Correlation of Endotheliitis With HAI Scores
More Severe Portal and Central Subendotheliitis in ACR
The severity of endotheliitis in ACR group was also examined and compared with that of other groups. As is shown in Table 5 , mean scores of portal and central subendotheliitis in ACR group (3.09 ± 0.62 and 1.95 ± 1.36, respectively) were significantly higher (all P<0.00005 ) than those in the HCV (1.63 ± 0.95 and 0.26 ± 0.32, respectively), HBV (1.44 ± 1.17 and 0.26 ± 0.40, respectively), and NASH group (0.35 ± 0.69 and 0.14 ± 0.52, respectively). NS indicates not significant
Comparison of 4-tier and 3-tier Scoring Systems for Endotheliitis
Results of statistical analyses based on the 3-tier scoring system remained essentially the same as those obtained with the 4-tiered system detailed in Table 1 . Specifically, scores for portal subendotheliitis remained significantly higher in both the HBV (mean score 1.15 ± 0.79) and HCV (mean score 1.36 ± 0.65) groups when compared with the NASH group (mean score 0.30 ± 0.51, P = 0.0004 and <0.00005, respectively). Similarly, the scores for portal subendotheliitis in the ACR group (mean score 2.48 ± 0.64) remained significantly higher than those in the HBV, HCV, and NASH groups (all P<0.00005). These results may inform a practical diagnostic application of our study design. Nonetheless, we prefer the 4-tier scoring system for purposes of data presentation in this report because pattern-based distinctions provided within the intermediate severity group remain useful and because the overall statistical relationships between endotheliitis pattern and severity in NASH, viral hepatitis, and ACR are well represented using this approach.
DISCUSSION
Endotheliitis is an important diagnostic feature of ACR in liver allografts, but because it may also be encountered with regularity in recurrent viral hepatitis, the demonstration of endotheliitis in a biopsy from a liver allograft may present the pathologist and hepatologist with a significant diagnostic dilemma. In this study, we evaluated the incidence and severity of endotheliitis in chronic liver disease, and compared the results to those in ACR. We focused on chronic hepatitis B and C and NASH because these are among the more common chronic liver diseases that may eventuate in liver transplantation, and disease recurrence is not uncommon in the liver allograft. This is particularly true of hepatitis C; which almost universally recurs after liver transplanta-tion. 6, 16, 8 Recognition of recurrence of primary disease in the allograft and the reliable separation of recurrence and ACR are crucial elements of posttransplantation management, because both the approach to management and the treatment modalities employed are significantly different. Misinterpretation of clinical or histologic indices in these patients (in particular, the misdiagnosis of recurrent disease as cellular rejection) may result in the unnecessary administration of immunosuppressive regimens, potentially precipitating serious complications such as opportunistic infection or worsening viral infection.
Typical histologic features of chronic hepatitis C include lymphoid aggregates within the portal tracts, mild macrovesicular fatty change, bile duct damage with lymphocytic infiltrate of the biliary epithelium (also known as the ''Poulsen lesion''), and a mild degree of lobular injury. 9 Similarly, chronic hepatitis B often causes interface hepatitis, and lymphoplasmacytic infiltrates in portal tracts and lobules. These features, however, are by no means pathognomonic of either viral disease. Indeed, many of these characteristics overlap with the typical features of cellular rejection, particularly portal/periportal inflammation and intraepithelial lymphocytes in biliary epithelium, based on current Banff criteria. 5 This morphologic overlap is what has historically bolstered the relative value of endotheliitis as a marker of rejection (a tie-breaker-between cellular rejection and recurrent viral hepatitis), and it is our evolving understanding of the prevalence of this pattern of endothelial injury in viral hepatitis that forms the basis for the present study. Our results indicate that minimal to mild subendotheliitis is often observed in the portal tracts in chronic hepatitis C and B, that severe endotheliitis is generally quite uncommon in viral hepatitis (none of the cases examined exhibited a grade 4 endothelial injury and only 13 of 62 HCV were scored as grade 3 in portal subendotheliitis), and that the severity of endotheliitis correlates with inflammatory activity. In contrast, endotheliitis in ACR tends to be much more severe than that in viral hepatitis. We believe that these observations may provide the basis for more reliable separation of recurrent viral hepatitis from cellular rejection in the allograft recipient. Endotheliitis in ACR is usually manifested by portal infiltrates that undermine the portal veins and disrupt and lift up the endothelial surface (Fig. 1D) , sometimes imparting to the endothelium an appearance similar to that of a Roman aqueduct. 12, 1 In contrast, this degree and pattern of endotheliitis are only infrequently encountered in chronic hepatitis C in the native liver. As important as the recognition of this difference is the potential separation of viral hepatitis from cellular rejection, it must be recognized that qualitative differences may also exist in other histologic indices relevant to Banff criteria.
Liver grafts are most vulnerable to ACR within the first 6 months after transplantation. 12, 1 This time period also encompasses the first histologic evidence of recurrent hepatitis C in afflicted patients. 7 Notably, histologic changes are accentuated in the lobules in the early phase of hepatitis C infection. In the liver allograft, these early lobular changes include lobular disarray with enlarged Kupffer cells, increased sinusoidal lymphocytes, inflammatory foci with lytic necrosis, and increased number of lobular acidophil bodies. 10, 14 Parenthetically, this pattern of parenchymal inflammatory activity is also more severe in injection drug users who have recently contracted hepatitis C. 17 Although obvious lobular inflammatory foci favor a diagnosis of recurrent hepatitis C over ACR, it is often difficult to distinguish recurrent hepatitis C and rejection when portal and lobular inflammation are both present to a similar degree. The present study suggests that although endotheliitis can also be present in chronic hepatitis C, injury, and inflammatory infiltrate to the endothelium is significantly milder than those in ACR and well-formed lymphoid aggregates with germinal centers comprise the typical viral-induced portal infiltrate. The latter are also not often as close to the endothelial surface of portal venules as the mixed mononuclear inflammatory infiltrate of cellular rejection. It has been suggested that although lymphocytic cholangitis is usually more widespread in ACR (effectively involving most of the interlobular bile ducts), it is generally a milder and more localized phenomenon in chronic hepatitis C. 12 Nonomura et al 13 described the attachment of lymphocytes to the vascular endothelial surface (endotheliitis) in various liver diseases. They reported high incidences of portal vein endotheliitis in certain liver diseases, most important among them non-A, non-B hepatitis. It should be noted that hepatitis C virus was identified only 2 years before their study was published 4 and we can only assume that most cases of what would ultimately be recognized in this study as hepatitis C were included in the non-A, non-B hepatitis group. Therefore, the exact incidence and severity of endotheliitis in chronic hepatitis C could not be directly inferred from Nonomura's work, a conclusion that provided additional impetus to the present study. Given the current hepatitis C viral serology and RNA assays available, we were able to identify the occurrence and degree of endotheliitis in a precisely defined chronic hepatitis C cohort.
Using a well-established HAI, analysis of the HCV and HBV groups in this study revealed strong correlation between portal subendotheliitis with portal inflammation and periportal injury (interface hepatitis). Previously, Nonomura et al 13 showed that portal vein endotheliitis was more frequently found when histologic activity in non-A, non-B hepatitis increased. Comparison of the latter observation with the present analysis is compromised somewhat, as noted earlier, a point exaggerated by the use of the now obsolete terminology chronic active hepatitis. Even so, data from both studies clearly demonstrate that portal inflammatory infiltrates consisting predominantly of lymphocytes and plasma cells are common in all forms of chronic hepatitis. And, as noted earlier, lymphoid aggregates or follicles with germinal centers are frequently seen in hepatitis C and are now considered typical, though by no means pathognomonic, of that disease. 9 The exact mechanism by which endotheliitis occurs in chronic hepatitis C and B is not clear at the present time. Others have suggested that certain chemokine receptors are confined to vessels within portal tracts. 15 Whether or not this compartmentalization favors recruitment of lymphocytes to the vicinity of portal vessels remains enigmatic.
In our viral hepatitis group, especially hepatitis C, we observed a higher elevation of serum transaminase than in the NASH group (Table 2) . Because these 2 groups (viral hepatitis vs. NASH) have distinctly different patterns of liver injury and histopathology, 2,3 it is difficult to attribute differences in liver tests to endotheliitis. NASH has a unique histopathology, with accentuation of inflammatory infiltrates in zone 3; hence, it is not surprising that the portal endotheliitis in NASH is not a significant complication of this disorder, when compared with the viral hepatitis group.
In conclusion, our results indicate that minimal to mild subendotheliitis is frequently seen in the portal tracts of patients with untreated chronic hepatitis C and B, a finding that resulted from direct comparison with groups of nonalcoholic steatohepatitis and ACR. The degree of endotheliitis correlates with the level of inflammatory activity. These observations, in our opinion, have important clinical implications, potentially forming the basis for a reliable means of preventing the overdiagnosis of ACR in allograft recipients who are instead experiencing recurrence of their viral hepatitis. As a result, the unnecessary administration of immunosuppressive therapies to patients with recurrent hepatitis may be minimized. The impact of this finding on the mitigation of inadvertent mismanagement in this clinical setting awaits further study.
